login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Study says that there is no evidence to support concerns that neurodegenerative disease-associated proteins transmit Alzheimer’s or Parkinson’s disease


Tuesday, 12 Feb 2013 11:46
Pathological deposits of Alzheimer's disease and Parkinson's disease-associated proteins
Pathological deposits of Alzheimer's disease and Parkinson's disease-associated proteins

On 4 February 2013, in a study published online in JAMA Neurology, by David Irwin, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA, and colleagues, reported a first group of recipients of cadaver-derived human growth hormone (c-hGH) who do not appear to be at increased risk for Alzheimer and Parkinson disease despite their likely exposure to neurodegenerative disease-associated proteins and elevated risk of infectious prion protein-related disease.


Irwin et al looked for evidence for human-to-human transmission of Alzheimer disease, Parkinson disease, and related neurodegenerative disease-associated proteins in c-hGH recipients. (Image: A=AB, the main component of Alzheimer’s disease-associated plaques, B=Tau, the main component of Alzheimer’s disease-associated tangles, C=Alpha-synuclein, the main component of Lewy bodies in Parkinson’s disease).

The study included 34 routine autopsy patients and a group of c-hGH recipients in the National Hormone and Pituitary Program (NHPP). No cases of Alzheimer’s disease or Parkinson’s disease were identified, according to the study results.

“We found no evidence to support concerns that neurodegenerative disease-associated proteins underlying Alzheimer’s disease and Parkinson’s disease transmit disease in humans despite evidence of their cell-to-cell transmission in model systems of these disorders. Further monitoring is required to confirm these conclusions,” the authors added.




Add New Comment

Related Items


Most popular


Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis
Thursday, 02 Apr 2015
In a post-hoc analysis of the use of general anaesthesia in the MR CLEAN trial (Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands) ... Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis

Evidence builds for endovascular treatment of acute ischaemic stroke
Friday, 17 Apr 2015
With the publication of two more stroke trials, the evidence in favour of endovascular treatment in patients with acute ischaemic stroke has reached new heights. Data from SWIFT PRIME and REVASCAT ... Evidence builds for endovascular treatment of acute ischaemic stroke

Study suggests feasibility of Baby Trevo for treatment of distal cerebrovascular occlusions
Thursday, 14 May 2015
Diogo Haussen and colleagues (Emory University School of Medicine, Atlanta, USA) report that their initial data suggest that treatment of distal cerebrovascular occlusions with the Trevo XP ProVue 3x2... Study suggests feasibility of Baby Trevo for treatment of distal cerebrovascular occlusions

Features


New day in acute ischaemic stroke therapy
Friday, 17 Apr 2015
The newest generation of trials for acute ischaemic stroke, including MR CLEAN, ESCAPE, EXTEND IA and SWIFT PRIME, appear to have ushered in a new era in stroke therapy. Now, Joseph Broderick (... New day in acute ischaemic stroke therapy

Flow diverter technology for intracranial aneurysms
Tuesday, 31 Mar 2015
Gabor Toth writes for NeuroNews about the flow diverters that are currently available and the ongoing clinical trials that could have the potential to extend the indications of flow diverter therapy ... Flow diverter technology for intracranial aneurysms

Profiles


Robert E Harbaugh
Thursday, 14 May 2015
Robert E Harbaugh speaks to NeuroNews about how far neurosurgery has come, and as president of AANS ... Robert E Harbaugh

Joseph Broderick
Wednesday, 07 Jan 2015
Joseph Broderick speaks to NeuroNews about the future of neurology and his research, in particular, ... Joseph Broderick

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions